eromycin powder for suspension
square pharmaceuticals plc, gazipur - erythromycin - powder for suspension - 250 mg/5 ml
eromycin ds tablet
square pharmaceuticals ltd. 48 mohakhali c.a. dhaka-1212 bangladesh - erythromycin - tablet - 500mg - antibacterials for systemic use: macrolides
eromycin pfs powder for oral suspension
square pharmaceuticals ltd 48 mohakhali ca dhaka-1212 bangladesh - erythromycin - powder for oral suspension - 125 mg/5ml - antibacterials for systemic use: macrolides
aeromycin - 500 500mg film - coated tablet
dynasty pharmaceuticals; distributor: dynasty pharmaceuticals - azithromycin (as dihydrate) - film - coated tablet - 500mg
cycloserine - cycloserine capsule
macleods pharmaceuticals limited - cycloserine (unii: 95ik5ki84z) (cycloserine - unii:95ik5ki84z) -
lanoxin
pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg; ; ; ; ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.
lanoxin paediatric
pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml; - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.
lanoxin pg
pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.0625mg; ; ; ; ; digoxin 0.0625mg - tablet - 0.0625 mg - active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone pregelatinised maize starch purified water rice starch active: digoxin 0.0625mg excipient: indigo carmine lactose monohydrate magnesium stearate maize starch povidone purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.